Lilly's Retatrutide Shows Unprecedented Weight Loss in Phase III Trial
核心洞察
Retatrutide, an unapproved triple incretin agonist, has driven average weight loss of nearly 30 per cent in 18 months in clinical trials, roughly twice that of Wegovy.
Eli Lilly states retatrutide is not approved by any regulatory agency and is legally available only through its clinical trials, yet vials are widely sold online.
A June 2026 CBS News investigation found more than 120 websites selling or promoting retatrutide, including over 50 clinics staffed by licensed medical professionals.
Retatrutide, nicknamed "triple-G" or "Godzilla Ozempic," has become a social media phenomenon despite never having been approved by any regulatory agency. In clinical trials, participants lost on average nearly 30 per cent of their body weight over 18 months, making it roughly twice as effective as Wegovy. The drug is a triple incretin, targeting GLP-1 (搜索), GIP (搜索) and glucagon, whereas semaglutide (Wegovy, Ozempic) mimics only GLP-1 and tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP.
Manufacturer Eli Lilly states on its website that retatrutide has not been approved by any regulatory agency and is legally available only through Lilly's clinical trials, with anything sold outside those trials illegal and unverifiable for safety, purity or dosing. Nonetheless, a June 2026 CBS News investigation identified more than 120 websites selling or promoting the drug, including more than 50 clinics staffed by licensed medical professionals. US poison control data quoted in that report indicate a 265 per cent increase in cases attributed to drugs sold as retatrutide in the first four months of 2026 compared with the last four months of 2025.
Experts quoted in the article warn that unregulated injectables may not contain retatrutide at all, and that even genuine product carries unknown risks until tested in a population. Because the drug class suppresses appetite irrespective of starting weight, commentators flag particular danger for people with eating disorders or body dysmorphia. On the therapeutic side, a small trial in people with fatty liver disease (搜索) found 86 per cent of participants reached normal liver fat levels after five and a half months on the highest dose, and retatrutide's glucagon component may improve cholesterol.
https://www.sciencefocus.com/the-human-body/retatrutide-godzilla-ozempic-glp1-weight-loss-2